Abstract:With the successful clinical application of anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) monoclonal antibodies (mAb), targeting the PD-1/PD-L1 interaction has become a promising method for the discovery of cancer therapy. Due to the inherent limitations of antibodies, it is necessary to search for small-molecule inhibitors against the PD-1/PD-L1 axis. We report the design, synthesis, and evaluation in vitro and in vivo of a series of novel biphenyl pyridines as the inhibitors of PD-1/PD-L1. 2-(((2-Methoxy-6-(2-methyl-[1,1′-biphenyl]-3-yl)pyridin-3-yl)methyl)amino)ethan-1-ol (24) was found to inhibit the PD-1/PD-L1 interaction with an IC50 value of 3.8 ± 0.3 nM and enhance the killing activity of tumor cells by immune cells. Compound 24 displays great pharmacokinetics (oral bioavailability of 22%) and significant in vivo antitumor activity in a CT26 mouse model. Flow cytometry and immunohistochemistry data indicated that compound 24 activates the immune activity in tumors. These results suggest that compound 24 is a promising small-molecule inhibitor against the PD-1/PD-L1 axis and merits further development.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00010?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00010</a>.Data of PD-1/PD-L1 TR-FRET assay, in vivo antitumor activity study of compound 24, compound 1 and PD-L1 antibody, binding affinity of compound 1 and 24 to PD-L1 by microscale thermophoresis assay, and 1H NMR, 13C NMR, and HPLC spectra of the final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00010/suppl_file/jm1c00010_si_001.pdf">PDF</a>)Docking of compound 24 with PD-L1 from 5J89 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00010/suppl_file/jm1c00010_si_002.csv">CSV</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00010/suppl_file/jm1c00010_si_003.pdb">PDB</a>)This article has not yet been cited by other publications.

Design, synthesis, and biological evaluation of phenylcyclopropylamine-entinostat conjugates that selectively target cancer cells

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Design, Synthesis and Biological Activity of 4-(4-benzyloxy)phenoxypiperidines As Selective and Reversible LSD1 Inhibitors.

Design and synthesis of TH19P01-Camptothecin based hybrid peptides inducing effective anticancer responses on sortilin positive cancer cells

Design, synthesis and biological evaluation of a novel PSMA-PI3K small molecule drug conjugate

Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection

Optimization and Biological Evaluation of Novel 1 H -Pyrrolo[2,3- c ]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Tumor specific in situ synthesis of therapeutic agent for precision cancer therapy

Stimuli-Responsive Aptamer-Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release

Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Abstract 6583: Developing a selective cancer chemotherapy by small molecule-based targeting of PCNA protein

Molecular docking, 3D-QSAR, and molecular dynamics simulations of thieno[3,2-b]pyrrole derivatives against anticancer targets of KDM1A/LSD1

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer

Modularly Engineered Solid-Phase Synthesis Of Aptamer-Functionalized Small Molecule Drugs For Targeted Cancer Therapy

Abstract 367: Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection

A Leucine Aminopeptidase-Activated Theranostic Prodrug for Cancer Diagnosis and Chemotherapy.

Abstract 5784: Structure-based drug design against caPCNA for selective cancer chemotherapy development

Discovery of Phenyl-Linked Symmetric Small Molecules As Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives As Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.

Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators

2-(4-Chlorophenyl)-2-oxoethyl 4-Benzamidobenzoate Derivatives, a Novel Class of SENP1 Inhibitors: Virtual Screening, Synthesis and Biological Evaluation.